Back to Sectors

ELUT

ELUTIA INC.
2 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BULLISH | 70% | 5/15/2026 | margin expansionBULLISH | 90% | 5/15/2026 | debt restructureBEARISH | 80% | 5/15/2026 | earnings missNEUTRAL | 50% | 5/15/2026 | regulatory actionBULLISH | 70% | 5/15/2026 | margin expansionBULLISH | 90% | 5/15/2026 | debt restructureBEARISH | 80% | 5/15/2026 | earnings missNEUTRAL | 50% | 5/15/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 15

Non-GAAP gross margins increased to 66.5% due to a shift toward direct sales and end-user pricing.

margin expansion
70%
bullishMay 15

Fully repaid SWK Loan Facility and divested non-core assets to eliminate senior debt.

debt restructure
90%
bearishMay 15

Net loss of $7.5 million significantly exceeds quarterly revenue of $3.1 million.

earnings miss
80%
neutralMay 15

Aggressively pursuing FDA clearance for next-generation NXT-41 and NXT-41x platforms.

regulatory action
50%
bullishMay 15

Non-GAAP gross margins increased to 66.5% due to a shift toward direct sales and end-user pricing.

margin expansion
70%
bullishMay 15

Fully repaid SWK Loan Facility and divested non-core assets to eliminate senior debt.

debt restructure
90%
bearishMay 15

Net loss of $7.5 million significantly exceeds quarterly revenue of $3.1 million.

earnings miss
80%
neutralMay 15

Aggressively pursuing FDA clearance for next-generation NXT-41 and NXT-41x platforms.

regulatory action
50%

Filing History

10-QMay 15, 2026

The Q1 2026 filing depicts a company in a high-stakes transition. Elutia has successfully removed the immediate threat of bankruptcy by clearing its senior debt and divesting non-core assets, but it has yet to prove it can operate as a sustainable business. The tension lies between the impressive technical validation of its platform—evidenced by the Boston Scientific deal—and the harsh reality of its current burn rate and contractual obligations. Investors are now weighing a binary outcome: either the NXT-41x platform achieves FDA clearance and captures a significant share of the reconstructive surgery market, or the company exhausts its remaining cash before commercialization. The shift to direct sales has improved margins, but the scale of revenue remains insufficient to cover the overhead of a public company and its ongoing R&D ambitions. The coming quarters will be defined by the company's ability to manage its cash runway against the progress of its clinical pipeline.